Tag
The twiist AID system significantly improves glycemic control and patient satisfaction in insulin-treated type 2 diabetes over 13 weeks, demonstrating safety and effectiveness supported by complementary real-world and RCT data.
Automated insulin delivery (AID) systems, while transformative for type 1 diabetes management, currently lack pregnancy-specific adaptations, leaving a critical gap in care. This article highlights the urgent need to include pregnant women
A focused summary of the 2026 international position statement offering practical, safety-first recommendations for continuing or initiating continuous glucose monitoring, insulin pumps, and automated insulin delivery in non‑critically ill
This study elucidates how insulin sensitivity and glucose control in menstruating individuals with type 1 diabetes fluctuate across menstrual cycle phases, emphasizing gaps in current automated insulin delivery systems and guidelines.
This review synthesizes the landmark RADIANT trial findings, demonstrating the efficacy of transitioning patients from multiple daily injections to tubeless automated insulin delivery, while integrating broader evidence on genetic susceptib
Automated insulin delivery (AID) significantly improves glycemic control in insulin-treated type 2 diabetes, demonstrating greater HbA1c reduction and increased time in target glucose range compared to traditional insulin delivery methods.
The LENNY trial demonstrates that the MiniMed 780G automated insulin delivery system improves glycaemic control and maintains safety in children aged 2–6 years with type 1 diabetes.
